The aim of this retrospective study is to assess real world practice of venetoclax dosing in CLL and determine whether dose reductions/cessation affect efficacy. The findings from this study will provide valuable information on efficacy of low dose venetoclax and its potential for reduced toxicity in combination therapy.

Update 19 February 2026 – Some sites, 7 or 8, have started collecting, then ethics & governance underway for the rest

Update 1 June 2026 – 6 sites taking park, some are already collecting

Update 17 Sept 2026 – starting data analysis